earn digital currency Top Block

Dizhe Pharmaceutical announced that the company's private placement plan has been approved by the Shanghai Stock Exchange. This is the first time that the refinancing of the unprofitable enterprise on the Shanghai Stock Exchange has been approved since the release of "Keba Article".Exempting the transfer of shares or units of REITs and the securities distribution business of option makers will enhance the competitiveness of Hong Kong REITs and reduce the transaction costs of option makers. Revising the stamp duty collection arrangement will promote the efficiency of stamping and stamp duty collection procedures in the paperless securities market environment.Statement: Personal opinion, for reference only!

The latest CPI data will be released tonight. The market expects the overall inflation rate to be 2.7%, 0.1 percentage point higher than that in October, and the core inflation rate is expected to be 3.3%, which is the same as that in October. Although the forecast data shows that the suppression of inflation by monetary policy is close to stagnation, it has dropped sharply compared with the previous peak of 9%. At present, the latest FEDWATCH data shows that the possibility of the Fed cutting interest rates next Tuesday is over 80%.This is a real long-term positive, which is manifested in three aspects: first, it is conducive to attracting investors to invest in the broad-based index through personal pension accounts; Second, it is helpful to inject new long-term funds into the capital market, optimize the investor structure, stabilize the market and promote the healthy development of the capital market; Third, it reflects the care of the regulatory authorities for the capital market and helps to enhance investors' confidence.Dezhe Medicine is a listed company in science and technology innovation board, and it is an innovation-driven biomedical company with global competitiveness. Therefore, its refinancing has been approved by the Shanghai Stock Exchange, which also shows that the supervision is tolerant of companies with core technology and hard power. Although it may not be ideal financially for the time being, it has broad prospects and great imagination, which is worthy of support.

At present, I am optimistic about tomorrow's trend. It is stronger than expected to maintain this trend today. Although the index has not increased much, the short-term trend at the daily level is still upward, and the quantity can be maintained. Should it continue to rise? The probability of continuing to close up tomorrow is still very high, and the short-term trend of the 60-minute level is to go well again.Dizhe Pharmaceutical announced that the company's private placement plan has been approved by the Shanghai Stock Exchange. This is the first time that the refinancing of the unprofitable enterprise on the Shanghai Stock Exchange has been approved since the release of "Keba Article".There will be no surprises on Thursday!